Skip to main content

Table 1 Background data of the population

From: Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF)

 Treatment group (n = 57)Control group (n = 57)
Age (years old)
 Mean69.071.6
 Standard deviation11.610.8
Gender
 Male45 (79%)41 (72%)
 Female12 (21%)16 (28%)
First treatment
 Yes49 (86%)53 (93%)
 No8 (14%)4 (7%)
Type of amputation
 Digital49 (86%)49 (86%)
 Transmetatarsal8 (14%)8 (14%)
Related pathologies53 (93%)57 (100%)
 Hypertension50 (88%)50 (88%)
 Chronic renal failure20 (35%)28 (49%)
 Hemodialysis6 (10%)1 (2%)
 Heart diseases35 (61%)43 (75%)
 Neurological disorders2 (4%)8 (14%)
 Autoimmune disorders1 (2%)
 Chronic respiratory failure9 (16%)14 (25%)
 Others9 (16%)10 (18%)
Smoke
 Yes11 (20%)8 (14%)
 Former23 (40%)24 (42%)
 No23 (40%)25 (44%)
Concomitant therapies57 (100%)57 (100%)
 Oral anticoagulant8 (14%)15 (26%)
 Antiplatelet53 (93%)53 (93%)
 Insulin37 (65%)46 (81%)
 OHAs32 (56%)25 (44%)
 NSAIDs8 (14%)9 (16%)
 Opioid6 (10%)7 (12%)
 Antibiotics10 (18%)6 (10%)
 Others7 (12%)3 (5%)
  1. Continuous data are presented as means and standard deviation. Categorical data are given as counts (%)
  2. OHAs oral hypoglycemic agents, NSAIDs non-steroidal anti-inflammatory drugs